Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 406 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: COVID-19 vaccine Clear all

Conditions: Covid19, Cancer, Malignancy, Vaccine Response Impaired
Interventions: SARS-COV2 Pfizer Vaccine; Biological
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Inflammatory Bowel Diseases
Interventions: Influenza vaccine, COVID-19 vaccine; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 64 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: COVID-19, Vaccine Reaction, COVID-19 Pandemic
Interventions: Moderna Booster Vaccine, Pfizer Booster Vaccine; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: SARS-CoV-2 Infection, COVID-19
Interventions: Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg, Placebo, Biological/Vaccine: BNT162b2 3mcg; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 6 Months to 15 Years
Enrollment: 11,837 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 90
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions: Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab; Drug
Lead sponsor: Jeffrey Curtis; Other
Eligibility: 18 Years to 85 Years
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more

Conditions: Pneumococcal Infection
Interventions: V110, V114, mRNA-1273, Placebo for V110, Placebo for V114; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 850 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 42
States / cities: North Hollywood, California • Northridge, California • Paramount, California + 38 more

Conditions: Pain, Injection Site Reaction, Adverse Drug Event
Interventions: Observational; Other
Lead sponsor: Duke University; Other
Eligibility: 5 Years to 15 Years
Enrollment: 299 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Oakland, California • Atlanta, Georgia • New York, New York + 2 more

Conditions: Metastatic Renal Cell Carcinoma
Interventions: DC vaccine, Bevacizumab, IL-2, IFN; Biological · Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: COVID-19 Vaccines
Interventions: BNT162b2; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 5 Years and older
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Homestead, Florida • Miami Lakes, Florida • Atlanta, Georgia + 10 more

Conditions: Viral Vaccines
Interventions: Influenza vaccination, SARS-CoV-2 vaccine, Zoster Vaccine Recombinant; Biological
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: Not listed
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions: CGM; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbia, Maryland

Conditions: COVID -19
Interventions: RVX-sCPD9; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: New York, New York • Durham, North Carolina • Cincinnati, Ohio + 1 more

Conditions: COVID-19 Respiratory Infection, Influenza
Interventions: COVID-19 Vaccine; Biological
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 44 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Covid-19 Vaccine, Vaccine Hesitancy
Interventions: Covid-19 vaccine education materials; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: San Francisco, California • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Myocarditis
Interventions: Not listed
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Multiple Sclerosis
Interventions: SARS-COV-2 mRNA Vaccine; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Denver, Colorado • New York, New York

Conditions: Influenza, Human
Interventions: Flu shot text messages; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 74,811 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Danville, Pennsylvania • Philadelphia, Pennsylvania

Conditions: SARS-CoV-2 Infection
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 25 Years
Enrollment: 15,028 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 65
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 51 more

Conditions: Malignant Glioma, Astrocytoma, Glioblastoma
Interventions: nivolumab, DC; Drug · Biological
Lead sponsor: Gary Archer Ph.D.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Vaccine Uptake
Interventions: Communication Campaign; Behavioral
Lead sponsor: Syracuse University; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Covid19
Interventions: SMS delivery of information, Personalized text message delivery of information, Interactive or 2-way SMS delivery of information; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,722 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Multiple Myeloma, Waldenstrom Macroglobulinemia, Immune System Disorder, Covid19
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Rheumatic Diseases
Interventions: Hepatitis A vaccine, Diphtheria, pertussis, and tetanus booster vaccine; Biological
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Northport, Alabama • Riverview, Florida • Boise, Idaho + 4 more

Search by objective public record fields.

Immune Response to the COVID-19 Vaccine

Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine

The BOOSTED (Booster Options Or Switching Tested for Effectiveness and Downsides Study) Trial (COVID-19)

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

COVID-19 VaccinE Response in Rheumatology Patients

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

Safety of Pediatric COVID-19 Vaccination

Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

A Study of COVID-19 Vaccine(s) in Children and Adults

Vaccine Responses in Cancer

Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes

A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine

Exercise and COVID-19 Viral T-cell Immunity

PROmotion of COvid-19 VA(X)Ccination in the Emergency Department - PROCOVAXED

A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)

A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans

Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates

Understanding the Long-term Impact of COVID on Children and Families

Nivolumab With DC Vaccines for Recurrent Brain Tumors

Boosting COVID-19 Vaccination Uptake Using Wastewater Surveillance

Equitable Access to COVID-19 Vaccines

Covid-19 Vaccine Responsiveness in MM and Waldenstrom

The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)